F5, Inc. (NASDAQ: FFIV), a multi-cloud application services and security company, on Monday announced financial results for the third quarter of 2023.
- Third-quarter revenue grew 4% to $703 million from $674 million in the same period of fiscal year 2022
- Global services revenue moved up 8% and product revenue rose 1% in the June quarter, reflecting a 5% systems revenue growth
- Net income, on a reported basis, was $89 million or $1.48 per share in Q3, compared to $83 million or $1.37 per share in the third quarter of 2022
- Third quarter adjusted profit increased to $194 million or $3.21 per share from $155 million or $2.57 per share last year
- Gross profit came in at $561 million during the three-month period, representing a gross margin of 79.8%
- For the fourth quarter, the company expects to deliver revenue in the range of $690 million to $710 million
- The management is looking for adjusted earnings in the range of $3.15 per share to $3.27 per share in Q4
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
